Safety of switching between rituximab biosimilars in onco-hematology
Abstract Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different biosimilars. In this prospective...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/68f49def5d11436693923505682f41e0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|